Anthera Pharmaceuticals (ANTH) Stock Price & Overview
NASDAQ:ANTH
Current stock price
The current stock price of ANTH is 0.117 null. Today ANTH is down by -56.67%. In the past month the price decreased by -46.82%. In the past year, price decreased by -92.78%.
ANTH Key Statistics
- Market Cap
- 3.063M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.59
- Dividend Yield
- N/A
ANTH Stock Performance
ANTH Stock Chart
ANTH Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ANTH. When comparing the yearly performance of all stocks, ANTH is a bad performer in the overall market: 97.94% of all stocks are doing better.
ANTH Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ANTH. Both the profitability and financial health of ANTH have multiple concerns.
ANTH Earnings
ANTH Forecast & Estimates
ANTH Financial Highlights
Over the last trailing twelve months ANTH reported a non-GAAP Earnings per Share(EPS) of -2.59. The EPS increased by 70.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -265.47% | ||
| ROE | -428.33% | ||
| Debt/Equity | 0 |
ANTH Ownership
About ANTH
Company Profile
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company's clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sj'gren's Syndrome, Graves' Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California.
Company Info
Anthera Pharmaceuticals
25801 INDUSTRIAL BOULEVARD SUITE B
HAYWARD CA 94545
CEO: J. Craig Thompson
Phone: 510-856-5600
Anthera Pharmaceuticals / ANTH FAQ
Can you describe the business of Anthera Pharmaceuticals?
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company's clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sj'gren's Syndrome, Graves' Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California.
Can you provide the latest stock price for Anthera Pharmaceuticals?
The current stock price of ANTH is 0.117 null. The price decreased by -56.67% in the last trading session.
What is the dividend status of Anthera Pharmaceuticals?
ANTH does not pay a dividend.
What is the ChartMill technical and fundamental rating of ANTH stock?
ANTH has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the market cap for Anthera Pharmaceuticals?
Anthera Pharmaceuticals (ANTH) has a market capitalization of 3.06M null. This makes ANTH a Nano Cap stock.